ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Long-term observation of treatment strategies for primary vitreoretinal lymphoma in a multicenter Chinese cohort.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo compare outcomes of different treatment regimens for primary vitreoretinal lymphoma (PVRL) without central nervous system (CNS) involvement, specifically assessing their association with subsequent onset of central nervous system lymphoma (CNSL).
methodsThis retrospective study collected data from 64 PVRL patients (118 eyes) from January 2015 to June 2023 at 4 ophthalmologic centers in China. Clinical, laboratory, and imaging data of these patients has been reviewed, focusing on the incidence of CNS manifestations during follow-up.
resultsAmong the 64 patients with PVRL, 26 patients received only intravitreal injection of methotrexate (group A), and 38 patients received combined intraocular and systemic treatment (group B). The median follow-up time was 36.1 months, the median CNS progression-free survival (PFS) was 23.5 months, and the median overall survival (OS) was not-reached. CNSL developed in 44 of the 64 patients (68.8%) during the follow-up, including 19 of the 26 patients (73.1%) in group A, and 25 of the 38 (65.8%) in group B. Increased cerebrospinal fluid IL-10 levels (range: 2.2-472 pg/ml, mean 63.715 pg/ml) were significantly correlated with the progression of CNSL (P < 0.001). In this observational cohort, combined therapeutic approach of systemic and intraocular therapy was associated with higher OS (P = 0.002). No significant differences in CNS-PFS was observed between the two treatment groups (P = 0.095).
conclusionIn this cohort of patients with PVRL, combined intraocular and systemic therapy may be associated with longer OS, while no significant difference in CNS-PFS was observed.
Indexed as
Identifiers
42461305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.